Clinical trial
A Single-arm, Open-label, Safety Rollover Trial of Obrixtamig in Patients With Different Tumours
NCT07929051 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open-label, Safety Rollover Trial of Obrixtamig in Patients With Different Tumours
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- March 4, 2027
- Completion date
- July 3, 2028
- Enrollment
- 68 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
advanced cancer
Arms
As registered; 1 arm.
-
Rollover arm
Patients who have previously received treatment with obrixtamig in another Boehringer Ingelheim-sponsored clinical trial (referred to as the 'parent trial') will be enrolled in this rollover study.
Treatment schedule and doses in the parent study will be continued in the rollover study.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Occurrence of treatment-emergent adverse events ( AEs) during the on-treatment period.
Lead sponsor's other trials
Boehringer Ingelheim, most recent start first.
+2,298 more trials See the organization page